Matthew K. Fust is an Independent Director of Sunesis Pharmaceuticals, Inc., since May 2005. He has been Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc., a biopharmaceutical company, since January 2009. Prior to joining Onyx, Mr. Fust was Executive Vice President and Chief Financial Officer at Jazz Pharmaceuticals, Inc., a pharmaceutical company, which he joined in May 2003. From May 2002 to May 2003, Mr. Fust was Chief Financial Officer at Perlegen Sciences, Inc., a biotechnology company. From June 1996 to January 2002, Mr. Fust was with ALZA Corporation, first as Controller and then as Chief Financial Officer. Mr. Fust holds a B.A. in Accounting from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.
Matthew Fust is 55, he's been the Independent Director of Sunesis Pharmaceuticals Inc since 2005. There are 4 older and 3 younger executives at Sunesis Pharmaceuticals Inc. The oldest executive at Sunesis Pharmaceuticals Inc is H. Ward Wolff, 71, who is the Director.
Matthew's mailing address filed with the SEC is 395 Oyster Point Blvd, South San Francisco, CA 94080, USA.
Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over $89,557,714 worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth $84,730,221 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of $14,060,191. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth $1,980.
Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: